X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9869) 9869
Publication (884) 884
Book Review (169) 169
Book Chapter (60) 60
Conference Proceeding (14) 14
Dissertation (11) 11
Magazine Article (10) 10
Newsletter (6) 6
Data Set (4) 4
Book / eBook (2) 2
Paper (2) 2
Web Resource (2) 2
Government Document (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5430) 5430
male (5428) 5428
animals (4481) 4481
index medicus (4242) 4242
phosphodiesterase inhibitors - pharmacology (2143) 2143
rats (2076) 2076
female (2064) 2064
pharmacology & pharmacy (2039) 2039
sildenafil citrate (1905) 1905
phosphodiesterase inhibitors - therapeutic use (1822) 1822
middle aged (1742) 1742
sildenafil (1665) 1665
adult (1454) 1454
erectile dysfunction (1430) 1430
erectile dysfunction - drug therapy (1307) 1307
phosphodiesterase (1251) 1251
mice (1232) 1232
phosphodiesterase inhibitors - administration & dosage (1191) 1191
aged (1189) 1189
urology & nephrology (1151) 1151
treatment outcome (1103) 1103
dose-response relationship, drug (1094) 1094
tadalafil (894) 894
neurosciences (868) 868
piperazines - therapeutic use (845) 845
impotence (826) 826
phosphodiesterase inhibitors (800) 800
purines (793) 793
analysis (774) 774
sulfones (771) 771
rats, sprague-dawley (747) 747
disease models, animal (736) 736
nitric oxide (718) 718
phosphodiesterase 5 inhibitors - therapeutic use (672) 672
nitric-oxide (661) 661
piperazines - administration & dosage (659) 659
administration, oral (654) 654
piperazines - pharmacology (648) 648
cardiac & cardiovascular systems (628) 628
drug therapy (627) 627
care and treatment (618) 618
cyclic amp - metabolism (618) 618
double-blind (618) 618
time factors (615) 615
phosphodiesterase inhibitors - adverse effects (595) 595
rats, wistar (590) 590
research (579) 579
double-blind method (574) 574
expression (572) 572
inflammation (512) 512
men (505) 505
health aspects (501) 501
hypertension, pulmonary - drug therapy (501) 501
biochemistry & molecular biology (494) 494
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (493) 493
respiratory system (492) 492
drug therapy, combination (491) 491
efficacy (488) 488
phosphodiesterase inhibitor (488) 488
cyclic gmp - metabolism (482) 482
rolipram (477) 477
pulmonary hypertension (476) 476
in vitro techniques (464) 464
therapy (461) 461
camp (459) 459
sulfones - therapeutic use (452) 452
phosphodiesterase 5 inhibitors - administration & dosage (448) 448
inhibitors (431) 431
medicine & public health (430) 430
hypertension (424) 424
piperazines - adverse effects (417) 417
risk factors (414) 414
inhibition (413) 413
physiology (412) 412
safety (408) 408
rodents (405) 405
dosage and administration (403) 403
sulfones - administration & dosage (393) 393
physiological aspects (391) 391
article (389) 389
nitric-oxide synthase (388) 388
hemodynamics - drug effects (387) 387
vasodilator agents - therapeutic use (383) 383
blood pressure - drug effects (381) 381
phosphodiesterases (381) 381
in-vitro (378) 378
cell biology (371) 371
phosphodiesterase 5 inhibitors - pharmacology (369) 369
sulfones - pharmacology (368) 368
erectile dysfunction - etiology (366) 366
phosphoric diester hydrolases - metabolism (364) 364
mice, inbred c57bl (362) 362
vardenafil dihydrochloride (360) 360
vardenafil (359) 359
cells, cultured (357) 357
purines - therapeutic use (356) 356
apoptosis (351) 351
cgmp (348) 348
activation (347) 347
penile erection - drug effects (346) 346
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9547) 9547
German (90) 90
Japanese (70) 70
Russian (59) 59
French (44) 44
Chinese (34) 34
Spanish (28) 28
Italian (12) 12
Hungarian (7) 7
Polish (7) 7
Portuguese (6) 6
Swedish (5) 5
Korean (4) 4
Norwegian (4) 4
Danish (3) 3
Turkish (3) 3
Bulgarian (1) 1
Croatian (1) 1
Czech (1) 1
Dutch (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Headache: The Journal of Head and Face Pain, ISSN 0017-8748, 04/2017, Volume 57, Issue 4, pp. 663 - 664
Journal Article
Journal Article
Chest, ISSN 0012-3692, 2013, Volume 144, Issue 3, pp. 952 - 958
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 09/2017, Volume 2017, Issue 9, p. CD002309
Background Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea and a reduction in lung function, quality of... 
COST-EFFECTIVENESS ANALYSIS | Administration, Oral | Humans | LUNG-FUNCTION | Pulmonary Disease, Chronic Obstructive [drug therapy] | Randomized Controlled Trials as Topic | CORTICOSTEROID/LONG-ACTING BETA-AGONIST | MEDICINE, GENERAL & INTERNAL | Benzamides [administration & dosage; adverse effects] | Cyclopropanes [administration & dosage; adverse effects] | Aminopyridines [administration & dosage; adverse effects] | Forced Expiratory Volume [drug effects] | Quality of Life | DOUBLE-BLIND | EXACERBATIONS | Phosphodiesterase 4 Inhibitors [administration & dosage; adverse effects] | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | Nitriles [administration & dosage; adverse effects] | COPD PATIENTS | LABA/LAMA/ICS TREATMENT | ROFLUMILAST | Cyclohexanecarboxylic Acids [administration & dosage; adverse effects] | Aminopyridines - administration & dosage | Forced Expiratory Volume - drug effects | Cyclohexanecarboxylic Acids - adverse effects | Aminopyridines - adverse effects | Cyclohexanecarboxylic Acids - administration & dosage | Cyclopropanes - adverse effects | Disease Progression | Nitriles - administration & dosage | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Nitriles - adverse effects | Benzamides - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 11, Issue 11, p. CD002309
Background Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea and a reduction in lung function, quality of... 
MANAGEMENT | Administration, Oral | Humans | Pulmonary Disease, Chronic Obstructive [drug therapy] | RANDOMIZED CLINICAL-TRIALS | COMBINATION | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | Benzamides [administration & dosage; adverse effects] | CILOMILAST | Cyclopropanes [administration & dosage; adverse effects] | Aminopyridines [administration & dosage; adverse effects] | Forced Expiratory Volume [drug effects] | Quality of Life | EXACERBATIONS | Phosphodiesterase 4 Inhibitors [administration & dosage; adverse effects] | QUALITY-OF-LIFE | CARDIOVASCULAR SAFETY | Nitriles [administration & dosage; adverse effects] | COPD PATIENTS | ROFLUMILAST | Cyclohexanecarboxylic Acids [administration & dosage; adverse effects] | BRONCHODILATORS | Aminopyridines - administration & dosage | Forced Expiratory Volume - drug effects | Cyclohexanecarboxylic Acids - adverse effects | Aminopyridines - adverse effects | Cyclohexanecarboxylic Acids - administration & dosage | Cyclopropanes - adverse effects | Nitriles - administration & dosage | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Nitriles - adverse effects | Benzamides - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
NeuroImage, ISSN 1053-8119, 11/2016, Volume 141, pp. 10 - 17
Journal Article
Journal Article
Respiratory Research, ISSN 1465-9921, 12/2011, Volume 12, Issue 1, pp. 1 - 10
As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy.... 
Medicine & Public Health | Pneumology/Respiratory System | OBSTRUCTIVE PULMONARY-DISEASE | RANDOMIZED CONTROLLED-TRIAL | RESPIRATORY SYSTEM | BURDEN | EPIDEMIOLOGY | Humans | Middle Aged | Aminopyridines - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Cyclopropanes - adverse effects | Lung - enzymology | Patient Selection | Cyclopropanes - therapeutic use | Forced Expiratory Volume | Benzamides - administration & dosage | Clinical Trials, Phase III as Topic | Anti-Inflammatory Agents - adverse effects | Benzamides - therapeutic use | Multicenter Studies as Topic | Aminopyridines - therapeutic use | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Female | Benzamides - adverse effects | Aminopyridines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Administration, Oral | Risk Factors | Proportional Hazards Models | Phosphodiesterase 4 Inhibitors - therapeutic use | Treatment Outcome | Lung - physiopathology | Pulmonary Disease, Chronic Obstructive - enzymology | Randomized Controlled Trials as Topic | Lung - drug effects | Aged | Research Design | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Patient outcomes | Dosage and administration | Research | Roflumilast | Drug therapy | Care and treatment | Bronchitis | Analysis | Studies | Hospitals | Statistical analysis | Mortality | Standard deviation | Hospitalization | Clinical medicine | Regression analysis | Manuscripts | Acquisitions & mergers
Journal Article
Journal Article